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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is more preva-
lent in men than women and this disparity cannot be fully explained by known risk
factors. Recent studies have shown that loss of Y chromosome (LoY) confers an
increased risk of solid cancer and reduces life expectancy in men.
Methods: Using publicly available data from The Cancer Genome Atlas, we inves-
tigated the prevalence of LoY and its association with clinicopathological features
in male HNSCC.
Results: LoY was detectable in around 25% of male HNSCC. Men with human
papillomavirus-negative tumors exhibiting LoY experienced significantly worse
overall survival than those with no LoY. Moreover, LoY tumors exhibited overex-
pression of genes involved in redox processes, including genes previously impli-
cated in resistance to both radiotherapy and cisplatin-based chemotherapeutics.
Conclusion: LoY may be an indicator of poor prognosis in male HNSCC that is
linked to the overexpression of genes associated with resistance to standard care
therapies.
KEYWORDS
aneuploidy, head and neck cancer, immune system, therapeutic resistance,
Y chromosome
1 | INTRODUCTION
Head and neck cancer is the sixth most common cancer
worldwide1 and can be categorized by anatomic subsite into
tumors of the oropharynx, nasopharynx, hypopharynx, oral
cavity, and larynx.2 Head and neck squamous cell carcinoma
(HNSCC) is the most common histological subtype, with
around six hundred thousand new cases worldwide each
year.2 The management of HNSCC consists mainly of
multiple-modality therapy with surgery, radiation, and chemo-
therapy. However, despite significant improvements in these
therapies, long-term survival rates in patients with advanced-
stage HNSCC have not increased significantly in the past
30 years, remaining around only 50% at 5 years.3
Smoking and alcohol consumption are well-established
risk factors for HNSCC, and may act synergistically during
tumor initiation.3,4 Although HNSCC exhibits considerable
genetic heterogeneity, mutations in the TP53 gene and chro-
mosomal instability are common features.3 In recent years,
infection with the human papillomavirus (HPV) has been
identified as a causative agent in around 25% of cases.2,5
HPV-positive cases mostly arise in the oropharynx,2 and
patients with these tumors are reported to have a better out-
come than patients with HPV-negative tumors.6 Although
the incidence of HPV-negative cancers appears to be declin-
ing as smoking becomes less common, HPV-positive can-
cers have become more prevalent in recent years.7
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Head and neck cancer is more prevalent in men than
women.1 Such sex imbalance is characteristic of many cancers,
and it is not adequately explained by differences in exposure
to key risk factors.8 This unexplained disparity raises the possi-
bility that underlying genetic differences between men and
women may make the former more susceptible to certain can-
cers, including tumors of the head and neck.
The most obvious genetic difference between the sexes is
that females have two X chromosomes, whereas males have
only one, maternally derived, X chromosome, and one Y chro-
mosome. Unlike the autosomes, the X and Y chromosomes
only recombine in two short regions at the tips of either arm,
called the pseudoautosomal regions (PARs). The vast majority
of the Y chromosome between the PARs is referred to as the
male-specific region. The Y chromosome is the third shortest
chromosome, and contains only a small complement of func-
tional genes as a result of millions of years of gene-decay since
the mammalian sex-chromosomes first evolved from a pair of
ancestral autosomes.9 However, there is mounting evidence
that despite the relative paucity of genes, the Y chromosome is
critically important for biological functions beyond its role in
male sex determination.10,11 In particular, loss of Y chromo-
some (LoY) is implicated in cancer. For example, recent stud-
ies of over 1000 elderly men showed that mosaic LoY in blood
cells is associated with smoking, an increased risk of non-
hematological cancer and impaired life expectancy.12,13
Although LoY has been documented in HNSCC,14 to date no
studies have reported its significance, either in terms of the under-
lying biology or clinical impact. Here, we report our findings on
the prevalence of LoY in male HNSCC, and its association
with clinicopathological features, based on analyses of publicly
available data from The Cancer Genome Atlas (TCGA).15
2 | MATERIALS AND METHODS
2.1 | Datasets used
The primary data used was TCGA's HNSC dataset. This
comprised 369 male and 135 female tumor samples.
The secondary dataset used comprised gene expression
data for 167 oral tumor samples (120 male), 17 oral dyspla-
sia samples (10 male), and 45 normal oral samples (32 male)
reported by Chen et al.16
For fluorescence in situ hybridization (FISH) analysis,
sections of a tissue microarray (TMA) containing oral,
oropharyngeal, hypopharyngeal, and laryngeal tumors were
obtained under ethical approval (10/H1210/9). These com-
prised, in particular, 27 male tumor samples.
2.2 | Copy number and mutation analyses using
TCGA data
Analyses of copy number variation were based on TCGA's
level 3 segmented copy number data produced using the
Affymetrix Genome-Wide Human SNP Array 6.0. These
data were downloaded from TCGA's data portal on February
5, 2015. We also downloaded clinical data in the “Biotab”
format and TCGA's level 2 somatic mutation data that had
been produced using the IlluminaGA DNASeq platform.
We used the copy number data based on version hg19 of
the human reference genome. For each sample, the seg-
mented data were used to calculate an average copy number
“index” for each chromosome and chromosome arm, as the
average copy number across the whole length of the chromo-
some/arm. The results were adjusted for tumor purity using
the TCGA clinical data item “tumor_nuclei_percent.”
To calculate the total autosomal aneuploidy index, for
each sample we summed the absolute differences between
two and the copy number index for each autosomal arm.
Data were not available for the short arms of the acrocentric
chromosomes 13, 14, 15, and 22, so these arms were
excluded from our analyses.
2.3 | Differential expression analyses
TCGA's level 3 RNA-sequencing data based on the Illumina
HiSeq 2000 RNA Sequencing (Version 2) platform were
downloaded. We used the files labeled “rsem.genes.results,”
which contained un-normalized read counts for over 20 000
genes. Read counts were normalized between samples and
converted to counts-per-million (cpm) reads for each gene
using the edgeR package17 in R.18 The same package was
used to perform differential expression analysis, using the
following criteria: fold-change  1.5, P < 0.05 (or <0.01
for HPV-negative cases), and cpm > 1 in at least the number
of samples in the smaller comparison group.
The raw CEL files used by Chen et al16 were downloaded
and reanalyzed using probe level quantile normalization,19 robust
multi-array analysis,20 and mas5 detection analysis. The “affy”
package in R was used for this purpose. Seven of 27 Y chromo-
some probes (“201909_at” gene = RPS4Y1, “230760_at” [ZFY],
“228482_at” [USP9Y], “205000_at” [DDX3Y], “236694_at”
[CYorf15A], “206700_s_at” [KDM5D], and “204409_s_at”
[EIF1AY]) were found to differentiate male and female sam-
ples. While analyzing the data we noticed that the sex of three
tumor samples (two males and one female) were inconsistent
with the expression data and were therefore changed.
For each of the seven probes, we calculated an expres-
sion ratio for each male sample as follows: (1) the average
female expression value across all female samples (assumed
to reflect “background” measurement) was calculated;
(2) the average female value was deducted from the expres-
sion value for each male sample; and (3) the female-adjusted
expression value was divided by the average female-adjusted
expression value for all male normal samples. Principal compo-
nents analysis was performed on the expression ratios to iden-
tify cases with LoY, reasoning that combining measurements
would reduce the impact of variability in the measurements for
individual probes. The “LIMMA” package in R was used for
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differential expression analysis, using the following criteria:
fold-change  1.5, P < 0.01, presence call of “P” in at least
the number of samples in the smaller comparison group.
Gene ontology analysis of differentially expressed genes
was performed using the Functional Annotation facility of
David (v6.8) and GOTERM_BP_DIRECT.21,22
2.4 | Statistical tests
All calculations were performed using R. The “Survival”
package was used for survival analyses. Comparisons of LoY
and aneuploidy levels between sample groups were performed
using the Kruskal-Wallis test. Correlation analyses were per-
formed using Spearman's method. Unless specified otherwise,
a significance level of 5% was used in all statistical tests.
2.5 | FISH analysis
TMA sections were deparaffinized in two changes of Ultra-
Clear (AVANTOR) each of 6 minutes followed by rehydra-
tion in two changes of 100% methanol each of 5 minutes.
Slides were immersed in 0.2 M HCl for 23 minutes and
washed in distilled water for 2 minutes. Spotlight paraffin
pretreatment solution (Invitrogen) was heated to 95C in a
water bath prior to immersing slides for 90 minutes, fol-
lowed by two washes in distilled water each of 2 minutes.
Three drops of enzyme digestion solution were added and
contained with a coverslip secured by a rubber sealant.
Slides were transferred to a humidified chamber at 37C for
60 minutes, coverslips were removed and slides washed
twice in distilled water for 2 minutes and then dehydrated in
methanol. Probe solutions for SRY (Vysis), XYq telomere
(Cytocell), and XYq (Cytocell) were labeled with fluores-
cein isothiocyanate (FITC) and tetramethylrhodamine iso-
thiocyanate (TRITC) and hybridized to TMA sections on the
HYbrite hybridization hot plate at 73C (Vysis)/75C
(Cytocell) for 2 minutes followed by 37C for 16 hours.
After hybridization, slides were washed in 0.4xSSC/0.3%
Nonidet-P40 and then in 2xSSC/0.1% Nonidet-P40 pre-
heated to 73C in a water bath for 2 minutes and 30 seconds,
respectively. The slides were air dried in the dark for 30 sec-
onds and then counter stained with 40,6-diamidino-2-pheny-
lindole (DAPI), mounted with a coverslip and kept in the
dark to protect the integrity of the probe. Signals were
recorded using the Olympus BX50 fluorescence microscope
at ×1000 magnification. Images were acquired using the
Metasystems CoolCube 1 and were analyzed using Meta-
System Isis software (MetaSystem).
3 | RESULTS
3.1 | LoY in a subset of males with HNSCC
We used TCGA's segmented copy number data to investi-
gate LoY in 369 male HNSCC. The data covered four of the
five main anatomical regions (Table 1). The most commonly
affected site was the oral cavity. HPV status was available
for 368 cases, of which 85 were classified as HPV-positive.
To measure LoY, we derived a Y chromosome copy
number index value for each sample based on the average
copy number across the whole male-specific region (the data
did not cover the PARs). This analysis revealed a bimodal
distribution of Y chromosome copy number index values for
the male tumor samples, with one peak at around 0.5, repre-
senting cases which had lost the Y chromosome, and a sec-
ond higher peak at around 1.0, representing cases which had
not lost the Y chromosome (Figure 1A). The bimodal distri-
bution was evident for both HPV-negative and HPV-positive
tumors when analyzed separately, but LoY was more com-
mon in HPV-negative cases (Figure 1B,C). For HPV-
negative cases, the peaks in the distribution occurred at 0.48
and 1.01. There were 81 (28.6%) cases to the left of the first
peak, 124 (43.8%) between the two peaks, and 78 (27.6%) to
the right of the second peak. For HPV-positive cases, the
two peaks occurred at 0.45 and 1.08, and the corresponding
breakdown of samples was 10 (11.8%) to the left of the first
peak, 38 (44.7%) between the two peaks, and 37 (43.5%) to
the right of the second peak.
Loss was mostly of the whole Y chromosome, although
there were some cases in which the long arm was lost but
the short arm was not lost (data not shown). We used the
RNA-seq data available on the same patients to identify
genes whose expression was correlated with the Y chromo-
some index. We identified 19 genes, all on the Y chromo-
some, for which there was a Spearman correlation of more
than 0.5 between gene expression and the Y chromosome
index (Table 2). These included all 12 genes previously
reported to be critical for male viability.10
Sufficient numbers of other male HNSCC with copy
number data were not available in the published literature.
Therefore, to confirm our observations of LoY in a separate
cohort, we took advantage of the global gene expression data
available on 119 male oral cancer samples reported by Chen
et al.16 Using principal components analysis based on the
expression ratios for the seven most discriminating probes,
we identified a subset of male cases with reduced expression
consistent with LoY. For the 119 tumor cases, a density plot
of the first principal component values revealed a bimodal
TABLE 1 Summary of The Cancer Genome Atlas (TCGA) male head and
neck squamous cell carcinoma (HNSCC) data
Site HPV-negative HPV-positive Total
Hypopharynx 1 (0.4%) 5 (5.9%) 6 (1.6%)
Oropharynx 20 (7.0%) 49 (57.6%) 69 (18.8%)
Larynx 88 (31.1%) 6 (7.1%) 94 (25.5%)
Oral cavity 174 (61.5%) 25 (29.4%) 199 (54.1%)
Total 283 85 368
Abbreviation: HPV, human papillomavirus.
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distribution similar to that found in the TCGA data
(Figure 1D).
Finally, to provide unequivocal evidence of LoY in male
HNSCC, we performed FISH on a separate cohort of 27 male
HNSCC using probes to detect the centromere of the Y chro-
mosome. Consistent with the data presented above, we
observed LoY in the tumor cells of 6 of 27 male HNSCC
samples (Figure 1E).
FIGURE 1 Loss of Y chromosome (LoY) in male head and neck squamous cell carcinoma (HNSCC). A, Density plot of Y chromosome copy number index
values for 369 male HNSCC. B,C, Density plots of Y chromosome copy number index values for 283 human papillomavirus (HPV)-negative and 85 HPV-
positive male HNSCC, respectively. D, Density plot of first principal component values for male oral cavity tumor cases from Chen et al. E, Representative
images of fluorescence in situ hybridization (FISH) analysis—X and Y chromosome probes shown in green and red, respectively: top left, female sample; top
right, male sample which has retained the Y chromosome; bottom panels, two male samples which have lost the Y chromosome [Color figure can be viewed
at wileyonlinelibrary.com]
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We conclude that around one-quarter of male HNSCC
are characterized by LoY.
3.2 | LoY may be linked to smoking in men with HPV-
negative HNSCC
LoY has previously been reported to be associated with both
smoking and increasing age.13,23
Data on smoking history at diagnosis (categorized as
“never smoked,” “stopped smoking more than 15 years
ago,” “stopped smoking within the last 15 years,” and “cur-
rent smoker”) were available for 359 TCGA patients with
known HPV status (Table 3).
For the HPV-negative cases, we found that the Y chro-
mosome index decreased across the smoking categories from
nonsmoker to current smoker, although this association was
only of borderline significance (Figure 2A, Kruskal-Wallis
P = 0.07). No such pattern was observed for the HPV-
positive cases (data not shown, Kruskal-Wallis P = 0.61).
We observed no statistically significant association between
age and LoY for either HPV subgroup (Figure 2B,C).
We conclude that LoY is not correlated with age, but
may be linked to smoking in men with HPV-negative
HNSCC.
3.3 | LoY is associated with shorter overall survival in
HPV-negative male HNSCC
We next investigated if LoY was associated with overall sur-
vival in men with HNSCC.
We first performed a univariate analysis of overall sur-
vival separately for males with HPV-negative or HPV-
positive cancer. For both groups, we compared samples in
which the Y chromosome index value fell outside the two
peaks of the bimodal distribution, thereby excluding cases
that lay between the two peaks and for which we were less
confident of LoY status.
We found that for HPV-negative HNSCC, LoY cases
had significantly shorter overall survival than non-LoY
cases, whereas for HPV-positive patients there was a similar
trend, but this was marginally not statistically significant
(Figure 3A,B, log-rank P = 0.003 and 0.06, respectively).
We next performed separate univariate survival analyses
for the same HPV-negative cases using each of the clinical
items shown in Table 4. We found that pathologic N had the
most statistically significant association with overall survival
(P = 0.002), closely followed by LoY status (P = 0.003)
and pathologic T (P = 0.006).
Univariate Cox proportional hazards analysis of all
HPV-negative patients using the Y chromosome index value
confirmed the association with overall survival (Wald test
P = 0.02). However, the Y chromosome index was no lon-
ger significantly associated with survival when considered in
a multivariate analysis with pathologic N, but did retain a
borderline significant association (Wald test P = 0.05) when
considered together with pathologic T. There was a clear
association between lower Y chromosome index and higher
pathologic T category (data not shown, Kruskal-Wallis
P = 0.0002).
Finally, we compared overall survival in males and
females with HPV-negative HNSCC. We found that HPV-
negative females with HNSCC had significantly longer overall
TABLE 2 Genes whose expression is highly correlated with Y
chromosome copy number index
Gene Correlation Location
KDM5Da 0.85 Long arm
CYorf15Aa 0.84 Long arm
DDX3Ya 0.83 Long arm
UTYa 0.82 Long arm
TTTY15 0.82 Long arm
EIF1AYa 0.81 Long arm
USP9Ya 0.80 Long arm
TMSB4Ya 0.78 Long arm
CYorf15B 0.75 Long arm
NLGN4Ya 0.73 Long arm
PRKYa 0.70 Short arm
ZFYa 0.66 Short arm
NCRNA00185 0.66 Long arm
RPS4Y1a 0.64 Short arm
NCRNA00230B 0.63 Long arm
TTTY14 0.58 Long arm
SFRS17A 0.56 PAR1 – Short arm
SRY 0.53 Short arm
TBL1Ya 0.53 Short arm
a Included in Bellott et al.10
TABLE 3 Breakdown of The Cancer Genome Atlas (TCGA) male head and neck squamous cell carcinoma (HNSCC) data by smoking history and TP53
mutation status
HPV-negative HPV-positive
Category Mutated Wild type N/A Mutated Wild type N/A
Never smoked 36 (87.8%) 5 (12.2%) 0 (0.0%) 3 (12.5%) 21 (87.5%) 0 (0.0%)
Stopped >15 y 25 (65.8%) 11 (28.9%) 2 (5.3%) 3 (25.0%) 9 (75.0%) 0 (0.0%)
Stopped <15 y 69 (84.1%) 11 (13.4%) 2 (2.4%) 6 (24.0%) 17 (68.0%) 2 (8.0%)
Current smoker 93 (81.6%) 14 (12.3%) 7 (6.1%) 9 (39.1%) 13 (56.5%) 1 (4.3%)
Total 223 (81.1%) 41 (14.9%) 11 (4.0%) 21 (25.0%) 60 (71.4%) 3 (3.6%)
Abbreviation: HPV, human papillomavirus.
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survival than male LoY cases, but significantly worse overall
survival than non-LoY cases (Figure 3C, P = 0.008).
We conclude that LoY is associated with significantly
shorter overall survival in males with HPV-negative HNSCC.
3.4 | LoY is associated with reduced expression of
immune genes and overexpression of redox-related genes
in male HNSCC
To determine if cases with LoY define a phenotypically dis-
tinct subset of male HNSCC and to identify genes that could
potentially explain the association between LoY and poorer
patient outcomes, we compared global gene expression in
cases with or without LoY. For each HPV subgroup, we
again compared cases for which the Y chromosome index
value fell outside the two peaks of the bimodal distribution.
We found that genes downregulated in LoY cases com-
pared with non-LoY cases were enriched for ontology terms
associated with immune-related functions, including
“immune response,” “adaptive immune response,” and
“inflammatory response.” Genes upregulated in this compar-
ison were enriched for genes with functions in “oxidation-
reduction process” (redox). These effects were evident in
both HPV subgroups (Tables 5 and 6).
Redox-related genes included members of the aldo-keto
reductase (AKR) family 1 (AKR1C1, AKR1C2, and
AKR1C3) and G6PD which have previously been linked to
resistance to cisplatin-based chemotherapy and
radiotherapy.24–26 We also observed similar differences in
gene expression when male LoY cases were compared with
female cases (data not shown).
Genes with immune-related functions were similarly
enriched when gene expression in LoY versus non-LoY
cases was compared in the data reported by Chen
et al (Supporting Information Table S1). Although we did
not observe a significant enrichment of genes involved in
redox processes among genes upregulated in this dataset, we
did observe the overexpression of some redox-related genes,
including AKR1C1 and G6PD.
We conclude that LoY in male HNSCC is associated
with the reduced expression of immune response genes and
the increased expression of genes involved in redox pro-
cesses and chemotherapy resistance.
3.5 | LoY is associated with significantly higher levels
of autosomal aneuploidy in HPV-negative male HNSCC
We next considered the possibility that LoY in male HNSCC
simply reflects chromosome instability. For each sample, we
derived a total (autosomal) aneuploidy index. Unlike the Y
chromosome index, the total aneuploidy index did not have a
bimodal distribution for either HPV subgroup (Figure 4A,B).
Furthermore, there was no significant association between
aneuploidy and smoking or age for either HPV subgroup
(data not shown).
We found that the Y chromosome index was inversely
correlated with the total aneuploidy index, but this was only
observed in the HPV-negative patients (Figure 4C,D). Split-
ting the HPV-negative male HNSCC cases as before
revealed that LoY cases had a significantly higher total aneu-
ploidy index than non-LoY cases (data not shown, Wilcoxon
P < 0.0001), although we also observed that there were
some highly aneuploid male tumors with no evidence
of LoY.
We next compared aneuploidy levels between male and
female HNSCC. We found that the total aneuploidy index
for HPV-negative male HNSCC was significantly higher
than for HPV-negative female HNSCC, but that this was not
the case for HPV-positive HNSCC (Figure 4E,F, Wilcoxon
FIGURE 2 Loss of Y chromosome (LoY) may be associated with
smoking history but not age for human papillomavirus (HPV)-negative male
head and neck squamous cell carcinoma (HNSCC). A, Violin plots of Y
chromosome copy number index values by smoking history for HPV-
negative male HNSCC—horizontal lines denote median values. B,C, Plots
of Y chromosome copy number index values against age at diagnosis for
HPV-negative and HPV-positive male HNSCC, respectively
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P < 0.0001 and P = 0.30, respectively). For the HPV-
negative cases, we refined our analysis by splitting the males
into those with or without evidence of loss of the Y chromo-
some (as previously), and also including those cases for
which the evidence was uncertain (ie, the samples whose Y
chromosome index values fell between the two peaks of the
bimodal distribution). We found that the male LoY cases
were significantly more aneuploid than not only the other
groups of male patients but also the female patients
(Figure 4G, Kruskal-Wallis P < 0.0001).
We then refined our analyses by further dividing cases
into those which did or did not have evidence of a somatic
mutation in the TP53 gene. Somatic mutation data were
available for 345 of the 359 male patients (Table 3).
Overall, 244 of 345 patients (70.7%) had evidence of a
mutation in TP53. The frequency of mutation was much
greater in HPV-negative cases (223 of 264 = 84.5%) com-
pared with HPV-positive cases (21 of 81 = 25.9%, Fisher's
exact test P < 0.0001).
We found that for HPV-negative male HNSCC, there
was no association between the Y chromosome index and
evidence of TP53 mutation, whereas for HPV-positive male
HNSCC, there was a statistically significant difference
between mutated and nonmutated cases, with the latter hav-
ing lower levels of LoY (Figure 5A,B, Wilcoxon test
P = 0.60 and 0.006, respectively). However, in contrast to
the LoY results, we found that HPV-negative male HNSCC
with evidence of TP53 mutation was significantly more
aneuploid than that without evidence of mutation, whereas
the difference for HPV-positive male HNSCC was not statis-
tically significant (Figure 5C,D, Wilcoxon P < 0.0001 and
P = 0.11, respectively). Finally, we found that for HPV-
negative HNSCC both with and without evidence of TP53
mutation, males with LoY were significantly more aneuploid
than other males and also females (Figure 5E,F, Kruskal-
Wallis P < 0.0001 and P = 0.003, respectively).
We conclude that in HPV-negative HNSCC, LoY in
males is associated with significantly higher aneuploidy
compared to both other males and females.
3.6 | LoY is strongly associated with the
overexpression of redox genes implicated in
chemotherapy resistance
We next considered the possibility that the differences in
gene expression we had observed between LoY and non-
LoY cases were primarily related to autosomal aneuploidy.
First, we ordered cases by total autosomal aneuploidy
index and compared global gene expression between the top
and bottom thirds. For both HPV-negative male and female
FIGURE 3 Loss of Y chromosome (LoY) is associated with shorter overall survival in male head and neck squamous cell carcinoma (HNSCC). Kaplan-
Meier plots of overall survival for male HNSCC in A, human papillomavirus (HPV)-negative cases split by LoY status; B, HPV-positive cases split by LoY
status; and C, HPV-negative cases split by LoY status and compared to HPV-negative females with HNSCC
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HNSCC, genes downregulated in highly aneuploid cases were
significantly enriched for immune-related genes, and those
upregulated were significantly enriched for genes involved in
redox processes (Table 7 and Supporting Information
Table S2), as we previously described for LoY. Enrichment
of immune-related genes was also observed among genes
downregulated in highly aneuploid HPV-positive male
HNSCC (data not shown), but there were too few HPV-
positive female cases for a meaningful comparison.
We next split the highly aneuploid male HNSCC into
LoY and non-LoY cases applying the same criteria as were
used earlier. For both HPV subgroups, we no longer
observed a significant enrichment of immune-related ontol-
ogy terms among genes downregulated in LoY cases (data
not shown). However, among the highly aneuploid HPV-
negative male HNSCC, we found that genes upregulated in
LoY versus non-LoY cases were still significantly enriched
for genes involved in redox processes and the metabolism of
chemotherapeutic drugs, again including AKR1C1,
AKR1C2, AKR1C3, and G6PD (Table 8).
In keeping with these observations, we found no evi-
dence of worse overall survival for highly aneuploid cases
(Figure 6, P = 0.19 and 0.33 for HPV-negative and HPV-
positive cases, respectively) and only a modest negative
effect in a univariate Cox proportional hazards analysis of
all HPV-negative male patients based on the total aneuploidy
index (Wald test P = 0.03).
We conclude that in male HPV-negative HNSCC, LoY is
associated with the overexpression of genes involved in redox
processes and the metabolism of chemotherapeutic drugs.
4 | DISCUSSION
Although LoY has previously been documented in male
head and neck cancer,14 to date its pathogenic significance
has been unclear. We took advantage of the large cohort of
HNSCC patients with clinical data available from TCGA to
TABLE 4 Summary of univariate survival analyses for human papillomavirus (HPV)-negative male head and neck squamous cell carcinoma (HNSCC)
patients
Item
Number of patients for
which data available
Categories used for Kaplan-Meier
analysis P value
Pathologic N 139 N0/N1/N2/N3 0.002
LoY status 159 Y index <0.48 vs > 1.01 0.003
Pathologic T 146 T1/T2/T3/T4/T4a/T4b 0.006
Perineural invasion 119 Yes / no 0.02
Pathologic stage 145 Stage I/II/III/IV 0.18
Histologic grade 153 G1/G2/G3/G4 0.49
TP53 mutation 155 Yes / no 0.31
Age (median split) 159 < median / > median 0.21
Smoking history 153 As described in text 0.94
Anatomic site 159 Oral cavity / larynx / oropharynx 0.92
Abbreviation: LoY, loss of Y chromosome.
TABLE 5 Genes differentially expressed in loss of Y chromosome (LoY)
cases for The Cancer Genome Atlas (TCGA) human papillomavirus (HPV)-
negative male head and neck squamous cell carcinoma (HNSCC)
Top 10 most significant gene
ontology terms
Term
No.
genes
Fold
enrichment P value
Downregulated genes in LoY cases
GO:0006955immune response 94 4.89 1.51E-38
GO:0006954inflammatory response 77 4.45 1.23E-28
GO:0002250adaptive immune
response
38 5.62 7.8E-18
GO:0070098chemokine-mediated
signaling pathway
25 7.71 3.27E-15
GO:0031295T cell costimulation 26 7.3 3.53E-15
GO:0007155cell adhesion 64 3.05 3.64E-15
GO:0060333interferon-gamma-
mediated signaling pathway
24 7.4 3.48E-14
GO:0007165signal transduction 112 2.11 4.13E-14
GO:0006935chemotaxis 30 5.38 1.33E-13
GO:0002504antigen processing and
presentation of peptide or
polysaccharide antigen via MHC
class II
13 16.74 3.74E-13
Upregulated genes in LoY cases
GO:0055114oxidation-reduction
process
40 2.88 5.92E-09
GO:0008652cellular amino acid
biosynthetic process
8 13.11 1.63E-06
GO:0008637apoptotic
mitochondrial changes
5 11.22 0.000867
GO:0097286iron ion import 3 42.62 0.0016
GO:0006749glutathione metabolic
process
7 5.33 0.0019
GO:0006805xenobiotic metabolic
process
8 4.37 0.0023
GO:0009612response to mechanical
stimulus
7 5.06 0.0025
GO:0001558regulation of cell
growth
8 4.26 0.0027
GO:0018916nitrobenzene metabolic
process
3 31.96 0.0032
GO:0006534cysteine metabolic
process
3 31.96 0.0032
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explore the prevalence of LoY in HNSCC, and its associa-
tion with clinicopathological variables, including outcome.
We showed that LoY is evident in around one-quarter of
male head and neck tumors, with higher prevalence in HPV-
negative compared with HPV-positive tumors, consistent
with the idea that these two subcategories have distinct aeti-
ologies.2 In our analysis of LoY in the TCGA data, the copy
number index rarely reached zero. This is probably
explained by the presence of a subset of nonmalignant cells
within each sample, as our results reflect the average copy
number across all cells, and our adjustment for tumor purity
could only make partial correction. Furthermore, there is the
possibility that only a subpopulation of tumor cells were
affected by LoY. Nonetheless, the FISH analysis, which is
able to directly identify LoY, suggested that our estimate of
LoY based on TCGA's copy number data closely approxi-
mates its true prevalence.
The results of our analysis of corresponding RNA-seq
data from TCGA, and from a separate cohort of male
HNSCC, confirmed our findings of Y chromosome loss. In
particular, we observed 19 Y-linked genes whose expression
in head and neck tumors was highly inversely correlated with
LoY. Previous analysis of the evolution of Y chromosomes in
eight different mammalian species identified 12 of these genes
(RPS4Y1, ZFY, TBL1Y, PRKY, USP9Y, DDX3Y, UTY,
TMSB4Y, NLGN4Y, CYorf15A, KDM5D, and EIF1AY)
that are crucial for male viability.10 Each of these 12 genes
has a homolog on the X chromosome which escapes X-inacti-
vation, suggesting that they are all dosage-sensitive. Further-
more, analysis of mutational signatures in over 8200 tumor/
normal sample pairs from several different tissue types has
suggested that two of these genes, UTY and ZFY, could be
tumor suppressor genes.27 UTY is of particular interest. Loss
of UTY is linked to increased cell proliferation in urothelial
bladder cell lines.28 Its X-chromosome homolog (UTX, also
known as KDM6A) is a demethylase of lysine 27 on histone
3 (H3K27), which is linked to dysregulated squamous cell dif-
ferentiation in HNSCC cell lines29; UTY may share this enzy-
matic activity, albeit at a reduced level.30 Loss of UTY has
also recently been implicated in both myeloid malignancies
and pancreatic cancer via demethylase-independent mecha-
nisms.31,32 There is also other experimental evidence to sup-
port the tumor suppressive effects of the Y chromosome. For
example, reintroducing a lost Y chromosome can suppress
tumor formation in a mouse model of prostate cancer,33
although this study did not establish the identity of the tumor
suppressor gene(s) responsible for this effect.
In keeping with the idea that the Y chromosome has
tumor suppressor functions, we observed that HPV-negative
males with LoY have significantly shorter overall survival
compared to their counterparts without LoY. Some caution
is required when interpreting these data, as the patients
had been treated with different regimes. Nonetheless, our
findings are consistent with a previous study based on a
much smaller cohort of HNSCC which had suggested that
LoY was associated with poorer patient outcomes.14
Our gene ontology analysis further emphasized the
possibility that LoY and non-LoY male HNSCC represent
biologically and clinically distinct subgroups. Of particular
relevance was the observation that genes upregulated in
LoY cases were significantly enriched for genes involved in
redox processes. Disruption of redox homeostasis, resulting
in elevated levels of reactive oxygen species in tumor cells
has been implicated in the promotion of tumor progression
and development of drug resistance.34 Genes upregulated in
LoY compared with non-LoY cases included members of
the AKRs superfamily of NAD(P)H-linked oxidoreductases,
such as AKR1B10, AKR1C1, AKR1C2, AKR1C3, as well
as ALDH3A1, G6PD, GPX2, PIR, SRXN1, and TXNRD1,
which are increasingly recognized for their important roles
in drug detoxification and xenobiotic metabolism.24–26,35–42
TABLE 6 Genes differentially expressed in loss of Y chromosome (LoY)
cases for The Cancer Genome Atlas (TCGA) human papillomavirus
(HPV)-positive male head and neck squamous cell carcinoma (HNSCC)
Top 10 most significant gene
ontology terms
Term
No.
genes
Fold
enrichment P value
Downregulated genes in LoY cases
GO:0006955~immune response 61 3.66 2.92E-18
GO:0002250~adaptive immune
response
36 6.14 4.76E-18
GO:0050852~T cell receptor signaling
pathway
29 4.95 4.26E-12
GO:0031295~T cell costimulation 21 6.8 1.51E-11
GO:0050776~regulation of immune
response
31 4.4 1.58E-11
GO:0042110~T cell activation 16 8.6 1.79E-10
GO:0006954~inflammatory response 44 2.93 5.02E-10
GO:0007165~signal transduction 89 1.94 2.22E-09
GO:0042102~positive regulation of T
cell proliferation
16 6.73 7.85E-09
GO:0002407~dendritic cell
chemotaxis
9 13.37 1.02E-07
Upregulated genes in LoY cases
GO:0055114~oxidation-reduction
process
31 2.81 6.78E-07
GO:0050729~positive regulation of
inflammatory response
9 6.61 6.12E-05
GO:0009636~response to toxic
substance
9 5.68 0.000181
GO:0031424~keratinization 7 7.82 0.00025
GO:0035725~sodium ion
transmembrane transport
8 5.88 0.000408
GO:0001523~retinoid metabolic
process
7 6.16 0.000923
GO:0008544~epidermis development 8 5.05 0.001
GO:0042574~retinal metabolic
process
4 17.88 0.0012
GO:0006094~gluconeogenesis 6 7.32 0.0013
GO:0030216~keratinocyte
differentiation
7 4.94 0.0029
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In particular, the upregulation of AKR1C1, AKR1C2, and
G6PD are all associated with resistance to cisplatin-based
chemotherapy in lung cancer,24,26 whereas upregulation of
AKR1C3 is linked to insensitivity to radiotherapy in
oesophageal cancer.25 In a recent study of head and neck
cancer, tumor redox was associated with poorer patient out-
comes, suggesting that its measurement, for example, by
62Cu-ATSM PET, could be a useful prognostic marker.43
FIGURE 4 Loss of Y chromosome (LoY) reflects an aneuploid phenotype in human papillomavirus (HPV)-negative male head and neck squamous cell
carcinoma (HNSCC). A,B, Density plots of total autosomal aneuploidy index values for HPV-negative and HPV-positive male HNSCC, respectively. C,D,
Plots of Y chromosome copy number index values against total autosomal aneuploidy index values for HPV-negative and HPV-positive male HNSCC,
respectively. E,F, Boxplots of total autosomal aneuploidy index values split by sex for HPV-negative and HPV-positive HNSCC, respectively. G, Boxplots of
total autosomal aneuploidy index values split by sex for HPV-negative HNSCC with males split by LoY status
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As expected, we found a close relationship between
LoY and autosomal aneuploidy, especially in patients with
HPV-negative cancer. Indeed, for these cases, autosomal
aneuploidy was found to be significantly higher, not only
when LoY male HNSCC were compared with non-LoY male
cases, but also when compared to female cases. These
observations are consistent with previous findings,44,45 and
raise the intriguing possibility that LoY may contribute to the
initiation of autosomal aneuploidy, potentially representing an
initial chromosomal mis-segregation event that triggers repli-
cation stress, DNA damage, and further genome and chromo-
some instability.46 In keeping with the possibility that LoY
FIGURE 5 Aneuploidy, but not Loss of Y chromosome (LoY), is associated with TP53 mutation in human papillomavirus (HPV)-negative male head and
neck squamous cell carcinoma (HNSCC). A,B, Violin plots of Y chromosome copy number index values by TP53 mutational status for HPV-negative and
HPV-positive male HNSCC, respectively—horizontal lines denote median values. C,D, Boxplots of total autosomal aneuploidy index values by TP53
mutational status for HPV-negative and HPV-positive male HNSCC, respectively. E,F, Boxplots of total autosomal aneuploidy index values for
HPV-negative HNSCC split by sex, with males further split by LoY status, for cases with or without evidence of a mutation in TP53, respectively
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could be an early event in HNSCC pathogenesis, our analysis
of the gene expression reported by Chen et al16 identified one
oral dysplasia sample with evidence of LoY (data not shown).
Notwithstanding the strong association between LoY
and autosomal aneuploidy, there are several reasons why we
believe that LoY may have pathogenic significance in its
own right. First, a subset of highly aneuploid male HPV-
negative cancers showed no evidence of LoY. Second, while
we observed a significant enrichment of redox-associated
genes also in highly aneuploid tumors, a comparison of LoY
and non-LoY cases in this subset revealed even higher levels
of redox-related gene expression among LoY tumors. Thus,
LoY apparently superimposes a higher redox state, even
among the most aneuploid cancers. Third, while LoY was
strongly associated with poorer overall survival in men with
HPV-negative HNSCC, we found less compelling evidence
of worse survival for highly aneuploid cases.
Previous work suggests that UTY, and KDM5D, which is
downregulated upon LoY, can epigenetically regulate innate
and adaptive immune responses.47,48 Furthermore, in Dro-
sophila, it has been shown that large regions of heterochroma-
tin within the Y chromosome may serve as genome-wide
regulators of biological functions, including immunity.49
Therefore, we were intrigued by the observation that LoY
was associated with decreased expression of immune-related
genes. However, when highly aneuploid male HNSCC were
split by LoY status, we no longer observed any enrichment of
immune-related ontology terms among genes downregulated
in LoY cases. Thus, the downregulation of genes with
immune-related functions appears to be primarily driven by
the strong association with aneuploidy. Consistent with this,
we also observed a strong association between aneuploidy
and the reduced expression of immune response genes in
female HNSCC. These observations are in keeping with the
findings of Davoli et al, who showed that across 12 human
cancers, including HNSCC, highly aneuploid tumors are
depleted for the expression of markers of cytotoxic infiltrating
immune cells, especially CD8+ T cells.50 Furthermore, their
analysis of data from two clinical trials of immune checkpoint
blockade therapy in metastatic melanoma revealed that
tumor aneuploidy inversely correlated with patient survival.
Therapeutic targeting of tumor immune suppression in
HNSCC is an active area of research, as only a small subset
of tumors responds to immune checkpoint inhibition.51 It
remains to be seen if LoY could be useful in identifying aneu-
ploid HNSCC and hence tumors that are less likely to respond
to immune checkpoint inhibitors.
TABLE 7 Genes differentially expressed in highly aneuploid The Cancer
Genome Atlas (TCGA) human papillomavirus (HPV)-negative male head
and neck squamous cell carcinoma (HNSCC)
Top 10 most significant gene
ontology terms
Term
No.
genes
Fold
enrichment P value
Downregulated genes in high aneuploidy cases
GO:0006955immune response 142 5.22 2.03E-64
GO:0006954inflammatory response 111 4.54 2.73E-43
GO:0060333interferon-gamma-
mediated signaling pathway
41 8.95 2.1E-29
GO:0007155cell adhesion 97 3.27 1.32E-25
GO:0045087innate immune
response
92 3.31 1.06E-24
GO:0002250adaptive immune
response
49 5.13 9.81E-22
GO:0060337type I interferon
signaling pathway
32 7.75 1.73E-20
GO:0050776regulation of immune
response
52 4.53 2.52E-20
GO:0070098chemokine-mediated
signaling pathway
33 7.2 6.58E-20
GO:0006935chemotaxis 42 5.33 2.09E-19
Upregulated genes in high aneuploidy cases
GO:0030855epithelial cell
differentiation
15 4.65 2.99E-06
GO:0060070canonical Wnt
signaling pathway
16 4.18 5.04E-06
GO:0055114oxidation-reduction
process
52 1.91 1.27E-05
GO:0030326embryonic limb
morphogenesis
9 4.88 0.000403
GO:0009954proximal/distal pattern
formation
7 6.33 0.000616
GO:0006749glutathione metabolic
process
10 3.87 0.00096
GO:0008652cellular amino acid
biosynthetic process
7 5.84 0.000974
GO:0009952anterior/posterior
pattern specification
12 3.25 0.0011
GO:0006600creatine metabolic
process
5 9.86 0.0011
GO:0007224smoothened signaling
pathway
11 3.46 0.0012
TABLE 8 Genes upregulated in loss of Y chromosome (LoY) cases
among highly aneuploid The Cancer Genome Atlas (TCGA) human
papillomavirus (HPV)-negative male head and neck squamous cell
carcinoma (HNSCC)
Top 10 most significant gene
ontology terms
Term No. genes
Fold
enrichment P value
GO:0055114~oxidation–reduction
process
30 3.85 9.55E-10
GO:0043651~linoleic acid
metabolic process
5 22.35 5.97E-05
GO:0006805~xenobiotic
metabolic process
8 7.79 7.23E-05
GO:0044597~daunorubicin
metabolic process
4 37.99 0.000118
GO:0044598~doxorubicin
metabolic process
4 37.99 0.000118
GO:0006098~pentose-phosphate
shunt
4 27.63 0.000339
GO:0008152~metabolic process 10 4.52 0.000377
GO:0097286~iron ion import 3 75.98 0.000508
GO:0006749~glutathione
metabolic process
6 8.14 0.000818
GO:0071395~cellular response to
jasmonic acid stimulus
3 56.99 0.001
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Previous research has suggested that LoY is associated
with smoking.13 We found a borderline association among
patients with HPV-negative tumors, although we were
unable to account for the effects of alcohol consumption as
data were unavailable for over half of the patients. Our
observation that LoY was less frequent among patients who
had stopped smoking compared to current smokers suggests
that the effects of smoking on LoY are potentially reversible,
which is consistent with previous research.13 We found no
significant association between age and LoY which is also
consistent with a previous report.52
In summary, our analysis revealed that LoY is a common
structural chromosomal abnormality in male HNSCC.
Although LoY is associated with aneuploidy, the strong
association between LoY and impaired survival linked to the
overexpression of chemotherapy resistance genes suggests
that LoY has distinct biological and clinical significance that
warrants further investigation.
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